DARE vs CRVS vs TPVG vs ABBV vs PFE

For growth investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger pick with 36. 6% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). TriplePoint Venture Growth BDC Corp. (TPVG) offers the better valuation at 4. 7x trailing P/E (6. 2x forward), making it the more compelling value choice. Analysts rate Corvus Pharmaceuticals, Inc. (CRVS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TriplePoint Venture Growth BDC Corp.

(TPVG) is the cheapest at 4. 7x versus AbbVie Inc. at 85. 0x. On forward P/E, TriplePoint Venture Growth BDC Corp. is actually cheaper at 6. 2x.

Over the past 5 years, Corvus Pharmaceuticals, Inc.

(CRVS) delivered a total return of +507. 4%, compared to -82. 2% for Daré Bioscience, Inc. (DARE). Over 10 years, the gap is even starker: ABBV returned +293. 8% versus DARE's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 28β versus Corvus Pharmaceuticals, Inc. 's 1. 57β — meaning CRVS is approximately 469% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Corvus Pharmaceuticals, Inc. (CRVS) carries a lower debt/equity ratio of 2% versus 133% for TriplePoint Venture Growth BDC Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TriplePoint Venture Growth BDC Corp.

(TPVG) is pulling ahead at 36. 6% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: Daré Bioscience, Inc. grew EPS 88. 4% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, ABBV leads at 1. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — TPVG leads at 83. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, TriplePoint Venture Growth BDC Corp.

(TPVG) trades at 6. 2x forward P/E versus 14. 2x for AbbVie Inc. — 7. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CRVS: 113. 3% to $33. 17.

In this comparison, TPVG (17.

8% yield), PFE (6. 7% yield), ABBV (3. 3% yield) pay a dividend. DARE, CRVS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 3% yield, +293. 8% 10Y return). Corvus Pharmaceuticals, Inc. (CRVS) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +293. 8%, CRVS: +24. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (DARE (Healthcare) and CRVS (Healthcare) and TPVG (Financial Services) and ABBV (Healthcare) and PFE (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: DARE is a small-cap quality compounder stock; CRVS is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock; PFE is a mid-cap income-oriented stock. TPVG, ABBV, PFE pay a dividend while DARE, CRVS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.